RD118, a new anti-GPRC5D #CARTtherapy, may be an effective therapeutic option in heavily pretreated cases of #MultipleMyeloma #MMsm, including those relapsing after BCMA therapy, according to phase I research resulting in a durable ORR of 94.4%: https://ow.ly/FQGQ50XXspe
#HemeSky #MyelomaSky

A frailty-score-adapted treatment regimen of an oral PI/IMiD combination improved early treatment cessation, PFS, and OS in unfit patients with #MultipleMyeloma #MMsm but not in frail patients, according to research to presented at #ASH25: https://ow.ly/rtun50XCYcp
#HemeSky #MyelomaSky

Combination treatment with #talquet­amab plus #daratumumab demonstrated deep, durable responses in patients with heavily pretreated R/R #MMsm #myeloma, with 71% and 82% achieving a response, and safety consistent with each as monotherapy: https://ow.ly/cSkt50Xv8vP
#HemeSky #MyelomaSky #OncSky

Talquetamab Bridging Therapy Enables Transition to BCMA CAR-T for Patients With High-Risk Myeloma | ASH Clinical News | American Society of Hematology

Bridging therapy with #talquetamab enabled patients with high-risk #myeloma #MMsm to successfully transition to #BCMA #CARTcell therapy, with 88% experiencing rapid disease control and proceeding to treatment with ide-cel or cilta-cel: ow.ly/7JkM50X8KYa
#HemeSky #MyelomaSky #MultipleMyeloma

#IMS25 full abstracts are out! #myelomasky #hemesky

Subcutaneous Isatuximab Noninferior to IV Administration in R/R MM | ASH Clinical News | American Society of Hematology

Subcutaneous #isatuximab delivered via an on-body injector was found to be noninferior to IV isatuximab plus #pomalidomide and #dexamethasone in patients with R/R #MultipleMyeloma #MMsm, with both methods resulting in comparable ORR and 12-month PFS: ow.ly/zJCh50WM6cl
#HemeSky #MyelomaSky #HemeOnc

Just spent an incredible 2 days lobbying state senators up in Sacramento on a bill to protect patients from medical debt. Thank you, Leukemia and Lymphoma Society for this amazing opportunity. #cancersky #myelomasky

Interesting paper #myelomasky
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy url:ashpublications.org/blood/article-abstract/d...

Some of our Stage 3/4/mets cancer support group at #nokings Chemo doesn't stop these bad asses from having our voices heard. #cancersky #myelomasky

Two friends passed from cancer yesterday. That makes 5 friends since my diagnosis with 1 still in hospice. Fuck you, cancer.💀 #cancersky #myelomasky

Now that the final #ASCO25 abstracts are out, here are my top #myelomasky ones

Etentamig
meetings.asco.org/abstracts-pr...

IberVd
meetings.asco.org/abstracts-pr...

5-Year Follow-up on CARTITUDE-1

meetings.asco.org/abstracts-pr...

It's my re-birthday today. Thank you to Dr. Robert Vescio at Cedars-Sinai in Los Angeles. #multiplemyeloma #cancer #myelomasky

As a myeloma patient, my risk of succumbing to infection has greater odds than my demise resulting from the cancer itself. The current regime cutting everything that made America great in order to give tax breaks to billionaires should worry everyone, not just cancer patients. #myelomasky #cancersky

Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+ @ireneghobrial.bsky.social #MyelomaSky

ashpublications.org/blood/articl...

Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells Key PointsAblation of Blimp-1 in anti-BCMA CAR T cells improves efficacy, representing a promising novel therapeutic product for MM.Transcriptomic analysis

Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells #MyelomaSky

ashpublications.org/bloodadvance...

Congrats, and happy to see your labor of love coming to fruitions Jonathan @pedalheadphx.bsky.social #MyelomaSky

Ask the Nurse: Blood tests in myeloma

Going for a blood test, waiting for results and then trying to make sense of the results can be extremely worrying. Our latest Ask The Nurse blog looks at some of the questions we get about blood tests. #myeloma #myelomasky www.myeloma.org.uk/library/ask-...

#MyelomaSky #HemeSky

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - PubMed Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineli...

Congrats for this important work. CEPHEUS study of Dara+VRd vs. VRd: MRD-negativity 60.9% for quad vs. 39.4% w/ VRd; ≥CR rates 81.2% vs. 61.6%; sustained MRD negativity (≥12 mos) 48.7% vs. 26.3%, 43% lower progression or death risk #MyelomaSky @szusmani.bsky.social pubmed.ncbi.nlm.nih.gov/39910273/

ASH2024 reflections: Advancing myeloma research

Myeloma UK was at #ASH2024 here's some of the things we learned and how it will impact our work going forward. www.myeloma.org.uk/news/ash2024... #myelomasky #myeloma #MGUS #SmoulderingMyeloma

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...

Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky

@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social

www.nature.com/articles/s41...

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma - Leukemia Leukemia - International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma #MyelomaSky

www.nature.com/articles/s41...

Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma - Nature Reviews Clinical Oncology Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients with high-risk smouldering multiple myeloma, which ch...

Perspective from @ireneghobrial.bsky.social and Omar Nadeem on early intervention with daratumumab for HR-SMM
#MyelomaSky #HemeSky

www.nature.com/articles/s41...

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study Key PointsD-R maintenance improved MRD-negative conversion rate in patients with NDMM who were MRD-positive after transplant vs R maintenance.PFS favored D

AURIGA study results:

- D-R maintenance improved MRD-conversion rate in NDMM patients who were MRD+ after transplant vs R maintenance.

- PFS favored D-R maintenance, with an improved 30-month PFS rate vs R alone; D-R was well tolerated

#MyelomaSky #HemeSky

ashpublications.org/blood/articl...

Depth of response is important in predicting better outcome not only in myeloma active disease (which led to MRD as an IE in ‘24) but also in precursor high-risk smoldering. Results of the I-PRISM phase II trial @ireneghobrial.bsky.social #MyelomaSky #HemeSky

www.nature.com/articles/s41...

Is it time to screen for multiple myeloma? In this issue, Visram et al1 make a significant advancement in the controversy of screening of multiple myeloma (MM) by providing an initial answer to the

Is it time to screen for multiple myeloma? @ireneghobrial.bsky.social #MyelomaSky #HemeSky

ashpublications.org/blood/articl...

#mmsm #myeloma #myelomasky

Why probability probably doesn’t exist (but it is useful to act like it does) All of statistics and much of science depends on probability — an astonishing achievement, considering no one’s really sure what it is.

So much of what we do in sciences is based on probability, yet we are not quite sure what it is - or even if it exists. #HemeSky #MyelomaSky

www.nature.com/articles/d41...

Hi #MyelomaSky peeps. Anyone has pics/slides from the ASH24 meeting showing all the GPRC5D mutations identified to date? I vaguely remember Paola Neri showed something but I can’t dig it up.

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | NEJM Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a...

Should patients with high-risk smoldering myeloma receive daratumumab? #MyelomaSky www.nejm.org/doi/full/10....